Abstracts tagged "Lupus"

Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Maureen A. McMahon¹, Jennifer M. Grossman², Lori Sahakian³, Christina Charles-Schoeman⁴, John Fitzgerald¹, Mihaela Taylor⁴, Alan Gorn¹, Eloise Olmos¹, Daniel J. Wallace⁵, Bevra H Hahn^1,4 and Brian Skaggs⁴, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…
Abstract Number: 2129 • 2018 ACR/ARHP Annual Meeting
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Jing Jing Wang¹, Alexander Colella¹, Dimitra Beroukas², Tim Chataway³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, SA Pathology, Adelaide, AR, Australia, ³Proteomic Facility, Flinders University, Adelaide, Australia, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Anti-double-stranded (ds)DNA autoantibodies are prototypic serological markers of systemic lupus erythematosus (SLE) but little is known about their immunoglobulin variable (IgV) region composition at…
Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 897 • 2017 ACR/ARHP Annual Meeting
Cutaneous Lupus Is Driven By an Exaggerated Interferon Kappa Loop Which Primes for Interferon Alpha Responses
Johann Gudjonsson¹, Mrinal Sarkar¹, Alex Tsoi², Celine C. Berthier³, Grace Hile⁴, Yun Liang⁴, Jianhua Liu⁵, Paul Harms⁶ and J. Michelle Kahlenberg⁷, ¹Dermatology, University of Michigan, Ann Arbor, MI, ²Departments of Dermatology and Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, ³Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁴University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Pathology, University of Michigan, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous inflammation is a common and disfiguring manifestation for 70% of patients with systemic lupus erythematosus, yet our understanding of the pathogenesis of cutaneous…
Abstract Number: 1618 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Development of Early Infectious and Non-Infectious Complications in Systemic Lupus Erythematosus Patients Undergoing Major Surgery
Lauro Quintanilla-González¹, Gonzalo Torres-Villalobos² and Andrea Hinojosa-Azaola³, ¹Immunology & Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Departmen of Experimental Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with increased cardiovascular and infectious complications due to subclinical atherosclerosis, disease activity and treatment-related factors. The…
Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Tony Muchamuel¹, Janet Anderl², R Andrea Fan², Henry W. B. Johnson³, Christopher J Kirk⁴ and Eric Lowe², ¹Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…
Abstract Number: 2986 • 2017 ACR/ARHP Annual Meeting
Omega Polyunsaturated Fatty Acids and Systemic Lupus Erythematosus (SLE): the Michigan Lupus Epidemiology & Surveillance (MILES) Program
Prae Charoenwoodhipong¹, Suzanna Zick², Wendy Marder³, Afton L. Hassett⁴, W. Joseph McCune⁵, Caroline Gordon⁶, Siobán Harlow⁷ and Emily C. Somers³, ¹University of Michigan, Ann Arbor, MI, ²Department of Family Medicine, University of Michigan, Ann Arbor, MI, ³Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁶Rheumatology Research Group, Institute of Inflammation and Ageing,, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Epidemiology Department- School of Public Health, Obstetrics and Gynecology- Medical School, University of Michigan, Ann Arbor, MI
Background/Purpose: Omega fatty acids have immunomodulatory properties; omega-3 (n-3) fatty acids are generally anti-inflammatory and omega-6 (n-6) pro-inflammatory. High n-6:n-3 ratios (up to 16:1) are…
Abstract Number: 223 • 2017 ACR/ARHP Annual Meeting
Decreased Medication Adherence Is a Major Cause for Increased Risk of Hospitalizations Among High Risk Lupus Patients
Caroline Thirukumaran¹, Katherine McCarthy², Jessica Patel³ and Allen P. Anandarajah⁴, ¹orthopedics, University of Rochester Medical Center, Rochester, NY, ²Pharmacy, University of Rochester Medical Center, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY
Background/Purpose: Low medication adherence in lupus has been associated with increased hospitalizations, more severe disease activity, and irreversible multi-organ damage. While lower socioeconomic levels, education,…
Abstract Number: 898 • 2017 ACR/ARHP Annual Meeting
B Cell Specific TLR9 Suppresses Disease in Murine Lupus
Jeremy Tilstra¹, Rachael Gordon², Shinu John³, Brady Marburger², Sheldon Bastacky⁴, Kevin Nickerson² and Mark Shlomchik⁵, ¹Rheumatology, Univ of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Moderna Therapeutics, Cambridge, MA, ⁴Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Toll-like receptor (TLR) signaling is a central to lupus pathogenesis. GWAS studies have repeatedly identified components of TLR signaling pathway in SLE patients. Furthermore,…
Abstract Number: 1626 • 2017 ACR/ARHP Annual Meeting
Childhood-Onset Predicts Increased Steroid-Related Damage Among Adults with Systemic Lupus Erythematosus
Merav Heshin-Bekenstein¹, Emily von Scheven², Aimee O. Hersh³, Laura Trupin⁴, Edward H. Yelin⁴ and Erica Lawson¹, ¹Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ²Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Childhood-onset SLE (cSLE) often presents with severe disease, managed with high-dose steroids. However, little is known about differences in long-term steroid toxicity between adults…
Abstract Number: 2562 • 2017 ACR/ARHP Annual Meeting
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Julie Di Paolo¹, Christopher Pohlmeyer¹, Zhi-Hua Cui², Gundula Min-Oo¹, Igor Mikaelian³, Robert Brockett³, Bernard Murray⁴, Roy Bannister⁵, JiYun Kim⁶ and Franziska Matzkies⁷, ¹Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ²Fibrosis Biology, Gilead Sciences, Foster City, CA, ³Biology Core Support, Gilead Sciences, Foster City, CA, ⁴DMPK, Gilead Sciences, Foster City, CA, ⁵Drug Safety, Gilead Sciences, Foster City, CA, ⁶Biomarkers, Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, Foster City, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling in hematopoietic cells important in the initiation and progression of systemic lupus erythematosus (SLE), including those from…
Abstract Number: 232 • 2017 ACR/ARHP Annual Meeting
The Charla De Lupus (Lupus Chat)® Program: Assessing the Needs of Teens and Young Adults with Lupus and Their Caregivers to Develop a Family Model Nutrition and Fitness Intervention
Melissa T. Flores¹, Jillian Rose², Priscilla Toral¹, Lillian Mendez¹, Dariana M. Pichardo¹, Roberta Horton¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Pediatrics, Columbia University Medical Center, New York, NY
Background/Purpose: Studies show Hispanics/Latinos are significantly impacted by health disparities, with higher rates of obesity & diabetes than Whites. Combined with SLE & higher risk…
Abstract Number: 920 • 2017 ACR/ARHP Annual Meeting
Area-Level Predictors of Medication Nonadherence Among U.S. Medicaid Beneficiaries with Lupus: A Multilevel Study
Candace H. Feldman¹, Karen H. Costenbader², Daniel H. Solomon³, S.V. Subramanian⁴ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Among lupus patients, adherence to hydroxychloroquine (HCQ), the backbone of therapy, remains suboptimal. Individual-level factors, including younger age, poverty, and black race, have been…
Abstract Number: 1643 • 2017 ACR/ARHP Annual Meeting
15 Year Comparative Analysis of Cardiovascular Events in Female Subjects with Lupus Versus Controls
Erika Joyce¹, Kristy Huysman², Linda Santelices², Michael Anderson², Amy H. Kao³, Jennifer Elliott⁴, Jennifer Mall², Amy Xiaoqin Tang⁵ and Susan Manzi², ¹Internal Medicine, Allegheny Health Network, Pittsburgh, PA, ²Medicine, Allegheny Health Network, Pittsburgh, PA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴Allegheny Health Network, Pittsburgh, PA, ⁵Lupus Center of Excellence, Allegheny Health Network Research Institute, Pittsburgh, PA
Background/Purpose: The multi-organ sequelae of systemic lupus erythematosus (SLE) may include nephritis, alveolar hemorrhage, and cardiovascular disease. Our long term follow up of female SLE…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].